louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04886375: Comparison of USG- Guided Modified Pectoral Nerve Block and Erector Spinae Plane Block on Postoperative Analgesia in Video Assisted Thoracoscopic Surgery
Official title: The Effect of USG- Guided Modified Pectoral Nerve Block and Erector Spinae Plane Block on Postoperative Analgesia in Video Assisted Thoracoscopic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Analgesia
Video-assisted Thoracoscopic Surgery
Lead sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2021-05-14
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to compare the effects of the erector spinae plan block (ESP) and modified pectoral nerve block (PECS II) on postoperative analgesia in patients undergoing video- assisted thoracoscopic surgery (VATS).

Detailed description: 55 patients (ASA I-II-III) between 18 and 65 years of age, who were to undergo VATS, were randomized and divided into two groups. (26 patients in each of the PECS and ESP groups). Three patients were excluded from the study because thoracotomy was performed. ESP block was performed for ESP group and a modified pectoral nerve block was performed in the PECS group. Postoperative analgesia was provided by intravenous morphine infusion using a patient-controlled analgesia device. Postoperative 24-hour total morphine consumption and duration of analgesia were the primary outcome measure. Perioperative remifentanil use, numeric rating scale values, time of the first analgesic request, and additional analgesic consumption were recorded.

Eligibility criteria: Inclusion Criteria:

* Ages of 18-65
* Patients who will undergo VATS
* ASA I-II-III patients

Exclusion Criteria:

* Clinically diagnosis of spinal or chest wall deformity or pathology
* Clinically known local anesthetic allergy
* Morbid obesity (body mass index\>40 kg m2)
* Clinically diagnosis of opioid, alcohol and substance dependence
* Clinically diagnosis of psychiatric disease
* Coagulopathy
* Patients with ASA IV-V

Primary outcomes:
measure: Postoperative 24-hours total morphine consumption
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: NRS scores of patients
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
state: Bakirkoy
Study officials:
References:
Clinical trial NCT06771375: Eye Movement Desensitization and Reprocessing (EMDR) to Treat Chronic Pruritus
Official title: Eye Movement Desensitization and Reprocessing (EMDR) to Treat Chronic Pruritus in a Multidisciplinary Tertiary Care Setting- a Feasibility Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Chronic Pruritus
Keywords: Eye Movement Desensitization and Reprocessing
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2025-01-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: non-randomized, open-label two-arm pre-post design feasibility-study
Primary purpose: TREATMENT

Brief summary: Pruritus is a common symptom of numerous dermatological and non-dermatological conditions. Current treatments for chronic pruritus (CP) are often not fully effective and may have burdensome side effects. Recently, the trauma exposure technique Eye Movement Desensitization and Reprocessing (EMDR) that is recommended as first line treatment for posttraumatic stress disorder has been reported to be also effective in the treatment of CP in anecdotal clinical case observations. However, to the best of the investigator's knowledge, the efficacy of EMDR in CP has not yet been systematically explored. This study aims at addressing this unmet need in a prospective pilot study comparing EMDR versus treatment as usual (TAU).


Eligibility criteria: Inclusion Criteria:

* Provided written informed consent
* Age 18 to 75 years
* Skindex-29 (questionnaire) symptoms subscale ≥42
* Confirmed diagnosis CP
* Itch intensity of min. ≥ 4 on the 0-10 numerical rating scale within the last 7 days
* Stable course of treatment in the two weeks prior to the study

Exclusion Criteria:

* Inability to follow the procedures of the study, e.g. due to language problems, severe psychiatric disorders such as delusional disorder, suicidality or dementia.
* Patients on phototherapy
* Acute attacks of an autoimmune disease such as Crohn's disease
* Serious cardiac disease

Primary outcomes:
measure: Adherence (%)
timeFrame: up to 8 month
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Chrysovalandis Schwale, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00246675: Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.
Official title: Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Renal Impairment After Cardiac Surgery
Lead sponsor: Melbourne Health
Sponsor class: OTHER
First posted: 2005-10-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

Detailed description: All patients will receive standard supportive care based on current established management practice of cardio-thoracic patients. The only difference in treatment will be the randomisation of patients to receive/not receive protocolised administration of frusemide targeting a urine output.

There will be 2 groups of patients. The control group-which will receive frusemide bolus doses if required as determined by the surgeon/consultant physician. The frusemide infusion group-which will be monitored to achieve a trial specified hourly urine output target range of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading dose of frusemide and may also then require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Eligibility criteria: Inclusion Criteria:

All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion, from the pre-admission clinics and wards of the Cardiothoracic surgery unit. Potential participants will be identified by the daily review of planned cardiothoracic surgery schedule.

Exclusion Criteria:

1. Already in established dialysis dependent chronic renal failure.
2. Known allergy to frusemide
3. Age \< 18 years
4. Pregnant

Primary outcomes:
measure: The incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery.
Secondary outcomes:
measure: 1. The maximum change in serum creatinine from baseline value during the first 7 days of hospital stay.
measure: 2. Incidence of renal failure requiring any form of renal replacement therapy.
measure: 3. Duration of post-operative hospital and ICU stay.
measure: 4. The maximum Sequential Organ Failure Assessment (SOFA) score in the first 7 days of hospital stay.
Other outcomes:
Locations:
city: Parkville
country: Australia
facility: Intensive Care Unit, Royal Melbourne Hospital
state: Victoria
Study officials:
affiliation: Royal Melbourne Hospital, Intensive Care Unit
name: John F Cade
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03965975: Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device
Official title: (In Spanish, Spain) "Validación Clínica Mediante Estudio analítico Con Muestras de Orina Para Comparar la Eficacia y Seguridad de un Smart Device"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Renal Insufficiency, Chronic
Heart Failure
Diabete Mellitus
Diabetes; Nephropathy (Manifestation)
Hematuria
Urinary Tract Infections
Lead sponsor: S-There Technologies SL
Sponsor class: INDUSTRY
Collaborators: name: Biocruces Bizkaia Health Research Institute
name: Hospital de Cruces
First posted: 2019-05-29
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The objectives of the Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device are:

1.To evaluate the performance of S-There Device in comparison to the golden standard used in the lab.


Eligibility criteria: Inclusion Criteria:

* Patients who came to the emergency room, primary care and nephrology unit.

Exclusion Criteria:

* Subject cannot collect urine in receptacle.
* Urinary Catheter

Primary outcomes:
measure: Accuracy to compared device
timeFrame: Through study completion, an average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Barakaldo
country: Spain
facility: Hospital de Cruces
state: Bizkaia
Study officials:
References:
Clinical trial NCT01961375: MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study
Official title: MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraception
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2013-10-11
Enrollment: 600
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study subjects will be enrolled from multiple sites like women's hospitals, tertiary care institutes, Family planning clinics and gynaecological consulting centres.

Brief summary: The study is designed as non interventional to observe the continuation rate and the patient satisfaction in women who have a LNG-IUS (Levonorgestrel releasing Intrauterine system) inserted for contraception over the period of 12 months under real life condition in India.The study will begin after the study approval by ethics committee.All Indian women aged between 18-49 years who are initiating LNG IUS therapy for contraception will be included in study after taking the informed consent.Patients will be observed for upto 12 months.The study involves general examination of patients, collection of data like medical history, previous contraceptive use,concomitant medication etc.The study is planned to enroll 600 subjects from multiple study centers spread across India. The study data will be analyzed with appropriate statistical methods.


Eligibility criteria: Inclusion Criteria:

* Subject aged between 18-49 years who are initiating LNG IUS therapy for contraception.
* Subject willing to provide informed consent and comply with study procedure.

Exclusion Criteria:

* Exclusion criteria must be read in conjunction with the local product information.

Primary outcomes:
measure: Percentage continuation rate of LNG IUS at end of observation period.
timeFrame: 12 months
measure: Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied
timeFrame: 12 months
Secondary outcomes:
measure: Cumulative discontinuation rate for pregnancy
timeFrame: 12 months
measure: Cumulative discontinuation rate for other medical reasons
timeFrame: 12 months
measure: Cumulative discontinuation rate for non-medical reasons
timeFrame: 12 months
measure: Mean percentage of women with amenorrhea
timeFrame: 12 months
measure: Mean percent of women with spotting, inter-menstrual bleeding
timeFrame: 12 months
measure: Distribution of contraceptive usage patterns
timeFrame: 12 months
measure: Incidence rate of drug-related adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Multiple Locations
country: India
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03072875: CAMS-RAS: for Suicide Prevention
Official title: CAMS Relational Agent System for Suicide Prevention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Suicide
Keywords: Suicidality
Collaborative Assessment and Management of Suicidality
Technology
Suicide Prevention
Suicide Intervention
Lead sponsor: Evidence-Based Practice Institute, Seattle, WA
Sponsor class: INDUSTRY
Collaborators: name: The Catholic University of America
name: University of Florida
First posted: 2017-03-07
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This Phase I feasibility study endeavors to create a prototype of a tool to determine its feasibility with suicidal patients in emergency departments (EDs). This is not a clinical trial. The overarching goal of this research is to create a tool that could reduce suicide rates, increase delivery of efficacious suicide interventions, and decrease overall costs associated with suicidal behaviors. SBIR Phase I project aims include: (1) creating an advisory board to guide the development of CAMS-RAS; (2) iteratively design and develop relational agent ("Dr. Dave") modeled after the gestures, expressions, and mannerisms of CAMS treatment developer, David Jobes, PhD; and (3) conduct feasibility tests to determine whether CAMS-RAS is acceptable, easy to use, and liked by target end-users: acutely suicidal patients admitted to hospital EDs, psychiatric inpatient units, and medical floors for treatment of injuries sustained during a suicide attempt; hospital medical personnel, administrators, and other stakeholders including peer advocates; and outpatient suicidal patients, clinicians and administrators.


Eligibility criteria: Patient Inclusion Criteria:

* English fluency
* 18 years or older
* receiving clinical care in a hospital or outpatient clinic for suicidality
* Suicidal patients currently admitted to EDs, psychiatric inpatient units, and medical floors, or patient with past (last 6 months) suicidality receiving outpatient treatment

Patient Exclusion Criteria:

* Acutely psychotic
* severely agitated (as determined by care team)

Primary outcomes:
measure: Usability Satisfaction and Acceptability Questionnaire (USAQ)
timeFrame: up to one day
measure: Number of ED Patient Participants Who Completed Semi-Structured Interview
timeFrame: After interacting with the technology (length: approximately 1 hour), subjects were then asked to complete the semi-structured interview conducted by the research assistant. On average, the interview lasted approximately 15 minutes.
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Evidence-Based Practice Institute
state: Washington
Study officials:
affiliation: Evidence-Based Practice Institute
name: Linda Dimeff, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00244075: Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients
Official title: Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: End Stage Renal Disease
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2005-10-25
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to evaluate the metabolic effects of concomitant use of three consecutive doses of recombinant human growth hormone over three days and exercise during continuous nutrient infusion in chronic hemodialysis patients. We would also like to evaluate the metabolic effects of nutritional supplementation alone without the additional anabolic strategies.


Eligibility criteria: Inclusion Criteria:

* On hemodialysis for more than 6 months, on a thrice weekly hemodialysis program;
* Adequately dialyzed (Kt/V \> 1.4).

Exclusion Criteria:

* Patients unable to perform exercise.
* Pregnant women.
* Severe unstable underlying disease besides commonly associated with ESRD. Cardiac patients that are stable will be included.
* Patients hospitalized within the last month prior to the study.
* Patients with recirculation detected on the AV graft.
* Patients receiving steroids and/or other immunosuppressive agents

Primary outcomes:
measure: net muscle protein balance
timeFrame: 10 hours
Secondary outcomes:
measure: net whole body protein balance
timeFrame: 10 hours
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Alp Ikizler, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pupim LB, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol. 2004 Jul;15(7):1920-6. doi: 10.1097/01.asn.0000128969.86268.c0.
citation: Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, Flakoll PJ. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E107-16. doi: 10.1152/ajpendo.2002.282.1.E107.
citation: Pupim LB, Flakoll PJ, Levenhagen DK, Ikizler TA. Exercise augments the acute anabolic effects of intradialytic parenteral nutrition in chronic hemodialysis patients. Am J Physiol Endocrinol Metab. 2004 Apr;286(4):E589-97. doi: 10.1152/ajpendo.00384.2003. Epub 2003 Dec 16.
citation: Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.
Clinical trial NCT00216775: Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C, Chronic
Lead sponsor: Kyoto University Hospital
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with chronic hepatitis C

Brief summary: The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses

Exclusion Criteria:

* Hemoglobin levels\<8.5g/dL,
* Platelet counts\<50,000/mm3,
* Total polymorphonuclear counts\<1000/mm3
* Pregnancy,
* Renal dysfunction,

Primary outcomes:
measure: rate of sustained viral response
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kyoto
country: Japan
facility: Department of Gastroenterology and Hepatology, Kyoto University Hospital
city: Osaka
country: Japan
facility: Kitano Hospital
city: Osaka
country: Japan
facility: Osaka Red Cross Hospital
city: Wakayama
country: Japan
facility: Wakayama Red Cross Hospital
Study officials:
affiliation: Kyoto University Hospital
name: Tsutomu Chiba, M.D., Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT06643975: Patient Satisfaction and Crestal Bone Changes Around One-piece Zirconia(Zr) and Titanium(Ti) in Implant-Retained Mandibular Overdenture
Official title: Assessment of Patient Satisfaction and Crestal Bone Changes Around One-piece Zirconia and Titanium Implants in Mandibular Implant-Retained Overdenture: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Complete Edentulism
Keywords: Zirconia
One-piece
Overdenture
Implant
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-10-16
Enrollment: 20
Sex: MALE
Minimum age (years): 50
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This interventional randomized clinical trial study is conducted to assess patient satisfaction and crestal bone changes around one-piece Zr and Ti Implants in mandibular implant-retained overdenture in completely edentulous male patients in the age group between (50-60)years old to know if there will be a significant difference between the two types of dental implants through 12 months after the definitive prosthetic loading


Eligibility criteria: Inclusion Criteria:

* Male patients
* The age range of 50 to 60 years old (average of 55).
* moderately developed mandibular residual ridges, covered with healthy mucosa, firmly attached to the underling bone and with average mucosal thickness (2-3) mm.
* At least 12 mm of vertical bone height in the mandible allowing for placement of a 10 mm implant (2 mm safety distance to inferior alveolar nerve).
* Patients were selected with Angle class-I maxillomandibular relationship with sufficient inter-arch space (13-15mm

Exclusion Criteria:

* Heavy smokers of more than 10 cigarettes a day
* Poor oral hygiene.
* Patients with temporomandibular joint disorders(TMD),
* Patients suffered of xerostomia,
* Patients exhibited Para-functional habits, or recent extractions were excluded.
* Patients with systemic diseases that might affect bone quality or quantity, or retard healing of the surgical wounds were excluded.
* Patients receiving intravenous forms of bisphosphonates.
* Patients who have had radiation therapy to the head and neck region.
* Patients with existing implants in the jaws
* Patients with previous bone grafting in either the maxillary or mandibular jaws.

Primary outcomes:
measure: Crestal bone changes
timeFrame: 12 months
Secondary outcomes:
measure: Patients Satisfaction
timeFrame: 12 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Ain Shams University
Study officials:
affiliation: Faculty of Dentistry, Benha University
name: Mohammad Irakky, masters
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Dentistry, Ain Shams Univeristy
name: Omnia M. Refai, PHD
role: STUDY_DIRECTOR
affiliation: Faculty of Dentistry, Ain Shams Univeristy
name: Noha Helmy Nawar, PHD
role: STUDY_DIRECTOR
References: